Aurobindo Pharma's board approved a ₹800 crore share buyback program involving 54,23,728 equity shares at ₹1,475 per share, representing 0.93% of paid-up capital. The buyback will be conducted through tender offer route with record date of April 17, 2026, targeting all shareholders including promoters on proportionate basis under SEBI regulations.

Aurobindo Pharma Approves ₹800 Crore Share Buyback at ₹1,475 Per Share

Aurobindo Pharma Limited's board has approved a significant share buyback proposal worth ₹800 crores at its meeting held on April 6, 2026. The pharmaceutical company will repurchase up to 54,23,728 fully paid-up equity shares at ₹1,475 per share, representing 0.93% of the total paid-up equity share capital.

Buyback Details and Structure

The board approved the buyback through the tender offer route, targeting all equity shareholders including promoters and promoter group members on a proportionate basis. The buyback will be conducted in accordance with SEBI (Buy-Back of Securities) Regulations, 2018 and the Companies Act, 2013.

Buyback Parameters: Details Total Shares: 54,23,728 equity shares Buyback Price: ₹1,475 per share Total Value: ₹800 crores Percentage of Capital: 0.93% of paid-up equity Record Date: April 17, 2026

The buyback size represents 3.93% and 2.62% of the aggregate total paid-up equity share capital and free reserves as per standalone and consolidated financial statements respectively as at March 31, 2025. Transaction costs including brokerage, fees, taxes, and other expenses are excluded from the buyback size.

Governance and Timeline

The board has constituted a buyback committee with delegated powers to execute all necessary actions for the buyback process. Under SEBI regulations, the board retains flexibility to increase the buyback price and decrease the number of shares until one working day prior to the record date, provided the total buyback size remains unchanged.

Meeting Details: Information Meeting Date: April 6, 2026 Meeting Duration: 7:00 AM to 8:10 AM Record Date: April 17, 2026 Regulatory Framework: SEBI Buyback Regulations 2018

Current Shareholding Pattern

As of December 31, 2025, the company's shareholding structure shows promoters and promoter group holding 51.82% with 30,09,48,721 shares. Mutual funds constitute the second-largest category at 19.52% with 11,33,67,285 shares, followed by foreign portfolio investors at 13.94%.

Shareholder Category: Shares Held Percentage Promoters & Promoter Group: 30,09,48,721 51.82% Mutual Funds: 11,33,67,285 19.52% Foreign Portfolio Investors: 8,09,91,628 13.94% Insurance Companies: 3,19,45,364 5.50% General Public & Others: 4,60,43,467 7.93%

The company will release the public announcement and letter of offer detailing the complete process, timelines, and other requisite information in due course as per regulatory requirements.

Aurobindo Pharma has announced an extension to its timeline for completing the acquisition of up to 26% stake in Swarnaakshu Solar Power Private Limited. The pharmaceutical company informed stock exchanges that the acquisition will now be completed on or before June 30, 2026, subject to receipt of approval from the concerned state government.

Updated Timeline and Regulatory Status

The company has extended its acquisition timeline due to pending receipt of state government approval for setting up a captive solar power plant. This represents a shift from the previously communicated timeline, as the company continues to await necessary regulatory clearances.

Parameter: Details Stake Acquisition: Up to 26% in Swarnaakshu Solar Power Private Limited Revised Timeline: On or before June 30, 2026 Project Type: Captive Solar Power Plant Approval Status: Pending state government approval

Previous Communications

The company has maintained regular communication with stock exchanges regarding this acquisition, with previous letters dated February 6, 2025, March 28, 2025, June 30, 2025, September 26, 2025, and December 30, 2025. The latest update reflects the ongoing regulatory process required for the captive solar power project.

Strategic Solar Investment

The acquisition remains part of the company's renewable energy strategy, involving both a captive solar power purchase agreement and the equity stake in Swarnaakshu Solar. The investment aligns with the pharmaceutical major's commitment to sustainable energy solutions and operational efficiency through renewable energy adoption.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.